Trial Profile
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Rilpivirine From Current INI-, NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-infected Adults Who Are Virologically Suppressed
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Rilpivirine (Primary) ; Antiretrovirals; Nucleoside reverse transcriptase inhibitors
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms SWORD-2
- Sponsors ViiV Healthcare
- 10 Nov 2023 Status changed from active, no longer recruiting to completed.
- 05 Feb 2023 Results of pooled analysis from SWORD-1 and SWORD-2 assessing drug exposure and exposure-efficacy/safety relationships, published in the British Journal of Clinical Pharmacology
- 26 Oct 2022 Results of pooled analysis assessing efficacy and safety (n=990; week 148) of switching to dolutegravir plus rilpivirine in virologically suppressed older populations living with HIV from SWORD-1 and SWORD-2 studies, presented at the 16th International Congress on Drug Therapy and HIV Infection.